Differential genetic diagnoses of adult post-lingual hearing loss according to the audiogram pattern and novel candidate gene evaluation

John Hoon Rim1,2,3 · Byunghwa Noh4 · Young Ik Koh1,5 · Sun Young Joo1,5 · Kyung Seok Oh1,5 · Kyumin Kim4 · Jung Ah Kim1,5 · Da Hye Kim4 · Hye-Youn Kim1 · Jee Eun Yoo4 · Seung-Tae Lee3 · Jin Woong Bok5,6 · Min Goo Lee1,5 · Jinsei Jung4,5 · Jae Young Choi4 · Heon Yung Gee1,2,5

Received: 25 March 2021 / Accepted: 8 September 2021 / Published online: 14 September 2021
© The Author(s) 2021

Abstract
Ski-slope hearing loss (HL), which refers to increased auditory threshold at high frequencies, is common in adults. However, genetic contributions to this post-lingual HL remain largely unknown. Here, we prospectively investigated deafness-associated and novel candidate genes causing ski-slope HL. We analyzed 192 families with post-lingual HL via gene panel and/or exome sequencing. With an overall molecular diagnostic rate of 35.4% (68/192) in post-lingual HL, ski-slope HL showed a lower diagnostic rate (30.7%) compared with other conditions (40.7%). In patients who showed HL onset before the age of 40, genetic diagnostic probability was significantly lower for ski-slope HL than for other conditions. Further analysis of 51 genetically undiagnosed patients in the ski-slope HL group identified three variants in delta-like ligand 1 (DLL1), a Notch ligand, which presented in vitro gain-of-function effects on Notch downstream signaling. In conclusion, genetic diagnostic rates in post-lingual HL varied according to audiogram patterns with age-of-onset as a confounding factor. DLL1 was identified as a candidate gene causing ski-slope HL.

Introduction
Hearing loss (HL) is the most common sensory disorder, affecting approximately one in every 500 newborns worldwide (Wilson et al. 2017). Since 2016, the application of next-generation sequencing (NGS) technology to determine the genetic causes of non-syndromic HL has enabled the identification of 26 additional genes for which variants have been linked to non-syndromic HL development; currently, more than 100 genes are implicated in the disease. However, the genetic heterogeneity and phenotypic variability of HL make it challenging to precisely identify causative variants and genes using NGS (Azaiez et al. 2018; DiStefano et al. 2019).
Although extensive attempts at genetic diagnoses have mainly focused on congenital or pre-lingual HL, including newborn screening for hereditary deafness (Dai et al. 2019; Shearer et al. 2019; Wang et al. 2019), genetic investigations in prospective adult-onset HL patient cohorts appear to be less definitive and more sophisticated owing to other confounding etiologies, such as noise-induced HL and presbycusis (Cunningham and Tucci 2017). For post-lingual HL, the audiogram serves as one of the most widely used phenotypic evaluation tools for HL and can provide decisive clues, particularly in terms of genotype–phenotype correlations (Taylor et al. 2013). Because a specific subset of genes determines hearing frequencies affected in various hearing impairments, physicians can predict the causative genes that correspond to certain types of audiograms with affected frequencies. Interestingly, the ski-slope audiogram pattern, which refers to a steeply down-sloping audiogram pattern with a high threshold observed for sounds with particularly high frequencies, is reportedly associated with pathogenic variants in TMPRSS3 (MIM 605511) in the autosomal recessive mode (DFNB8/10, MIM 601072) (Chung et al. 2014). Because post-lingual ski-slope HL is one of the most common HL types and patients commonly neglect the chances for diagnosis and treatment, the identification of genetic components for ski-slope HL is essential for both diagnostic and prognostic purposes.

Herein, we aimed to investigate the real-world molecular diagnostic rates of post-lingual HL according to audiogram patterns using a two-track strategy of gene panel and exome sequencing (ES) analyses. Furthermore, additional efforts were made to elucidate the genetic factors involved in ski-slope HL, identify the effects of delta-like ligand 1 (DLL1, MIM: 606582) variants, and determine the roles of Notch signaling in ski-slope HL.

Methods

Patients and panel/exome sequencing

In total, 192 families with post-lingual non-syndromic HL included in the Yonsei University Hearing Loss (YUHL) cohort were prospectively enrolled from January 2016 until June 2020 (Jung et al. 2017). The participants were enrolled in the YUHL cohort based on the following inclusion criterion: HL without congenital cytomegalovirus infection or other medical diseases primarily affecting hearing function. All individuals registered in the YUHL cohort were referred to Severance Hospital for further evaluation and treatment. Based on pure-tone audiogram patterns, we selected the ski-slope HL group; individuals in this group had audiograms with normal thresholds at low frequencies, but abruptly high thresholds at high frequencies. We defined ski-sloping HL as having a PTA4 (pure-tone average at 500, 1000, 2000, 4000 Hz) greater than or equal to 25 dB and PTAhigh to PTAlow greater than or equal to 25 dB (PTAlow, pure-tone average at 250, 500, and 1000 Hz; PTAhigh, pure-tone average at 2000, 3000, and 4000 Hz). Other individuals with audiogram patterns including flat, reverse, or fluctuating types were grouped into a separate HL group (hereafter, referred to the other HL group).

For molecular genetic testing, genomic DNA was extracted from leukocytes of whole blood samples using a QIAamp Blood DNA mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Two-track genetic analysis of panel sequencing and/or ES was performed according to the patients’ willingness for genetic testing when the payment was covered by the national government insurance system. For the customized NGS panel, we selected 207 HL causative genes with validated evidence based on an extensive literature review, the Hereditary Hearing Loss homepage (https://hereditaryhearingloss.org/), Deafness Variation Database (http://deafnessvariationdatabase.org/), and the Online Mendelian Inheritance in Man (OMIM) database (http://www.ncbi.nlm.nih.gov/omim; listed in Supplementary Table S1). For ES, pre-capture libraries were constructed using an Agilent SureSelect V5 enrichment capture kit (Agilent Technologies) according to the manufacturer’s sample preparation protocol. Pooled libraries were sequenced using a MiSeq sequencer (Illumina, San Diego, CA, USA) with the MiSeq Reagent Kit v2 (300 cycles).

Ethics statement

This study was approved by the institutional review board of Severance Hospital, Yonsei University Health System (IRB #4-2015-0659). We obtained written informed consent from individuals with HL for their participation in this study and the publication of their clinical data.

Identification of pathogenic variants in known HL genes for genetic diagnosis

Data analysis was performed using CLC Genomic Workbench (version 9.0.1) software (Qiagen) and our custom pipeline. Briefly, raw sequence data were mapped to GRCh37 (hg19) using the Burrows-Wheeler Aligner algorithm, followed by the removal of duplicate reads, realignment of insertions and deletions, base quality recalibration, and variant calling using the Genome Analysis Toolkit.
Quality metrics were calculated for each sample using FastQC software and TEQC package. Average read depth and coverage percentages were appropriate for further downstream analysis as quality control indices for NGS in the panel/ES results (Supplementary Table S2). Chromosomal copy number variations were detected using the EXCAVATOR version 2.2 and ExomeDepth version 1.1.10 tools with default settings. Identified variants were annotated, filtered, and evaluated for their pathogenicity using the following databases for pathogenicity evaluation: (1) gnomAD, Exome Aggregation Consortium, Exome Sequencing Project, dbSNP, 1000Genome, and Korean Reference Genome Database for allele frequency; (2) in silico prediction algorithms, including Sorting Tolerant from Intolerant, Polymorphism Phenotyping v2, MutationTaster, Condel, CADD, and REVEL scores; and (3) ClinVar, Deafness Variation Database, and Human Gene Mutation Database (HGMD professional v2020.4.). Final decisions on genetic diagnosis status in every patient were made by a board of genetic HL professionals, including clinicians, otolaryngologists, geneticists, laboratory personnel, and bioinformaticians, through review and discussion in a monthly consensus meeting, in accordance with the HL-specified ACMG guidelines (Oza et al. 2018).

**Clinical characteristics of the HL phenotype in association with genetic diagnosis**

To discover the association between HL phenotype and genetic diagnosis status, clinical characteristics of HL were comprehensively evaluated for all patients. Age of HL onset was categorized by early/mid/late decades. Deafness duration, which could also be termed as the lag time for genetic tests, was defined as the period between age of HL onset and age at genetic test. Vestibular symptoms, including spinning sensation and gait imbalance, were thoroughly tested by professional otologists. Detailed genetic counseling was performed by a clinical geneticist to inquire about family history and inheritance mode. From the family history analysis, simplex families included patients without any other affected family members, whereas multiplex families included those having multiple HL patients in a single pedigree.

**Candidate gene prioritization strategy**

From genetically undiagnosed cases with ski-slope HL, candidate genes with rare variants (i.e., variants with gnomAD minor allele frequencies lower than 0.1%/0.6% for genes with dominant/recessive inheritance modes, respectively) (Rim et al. 2019) from more than two families were prioritized based on gene-by-gene, variant-level, and affected individual-based analyses. For gene-by-gene evaluation, we determined cumulative allele frequencies for loss-of-function (LoF) variants of specific genes from the gnomAD database (Karczewski et al. 2020). The International Mouse Phenotyping Consortium (IMPC) database (Dickinson et al. 2016) was searched for abnormal results in auditory brain-stem response of mouse models to identify candidate genes. For variant-level analysis, the types and locations of variants with different protein domains were considered for prioritization. Affected individual-based analysis included identification of the progressive nature of HL and an inheritance pattern in the pedigree of individuals with ski-slope HL.

**In vitro experimental functional analysis for candidate gene variants**

For functional analysis of variants in candidate genes, surface biotinylation, coculture assay, real-time polymerase chain reaction (PCR), and western blotting were performed for in vitro evaluations. Human embryonic kidney 293 T (HEK 293 T) and HeLa cells were cultured in Dulbecco’s modified essential medium (DMEM) supplemented with 10% fetal bovine serum and penicillin (50 μg/mL)/streptomycin (50 μg/mL; Invitrogen, Carlsbad, CA, USA). Cells were transfected with wild-type (WT) or mutant DLL1 plasmids using Lipofectamine and PLUS reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Surface biotinylation was assessed using 0.3 mg/mL EZ-Link Sulfo-NHS-SS-Biotin and NeutrAvidin (Thermo Fisher Scientific). Cells were homogenized in lysis buffer containing 50 mM Tris (pH 7.4), 1% NP40, 150 mM NaCl, and 1 mM ethylenediaminetetraacetic acid (EDTA) supplemented with a protease inhibitor mixture (Roche). For coculture experiments, HEK 293 T cells transfected with a human NOTCH1 expression plasmid (AddGene) were cocultured with HEK 293 T cells transfected with WT or mutant DLL1 plasmids 24 h prior to coculture. Experiments were performed within 24–36 h after coculture. For real-time PCR, RNA samples were isolated with RiboEx (Gene-All Biotechnology) and reverse-transcribed with an iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA). Samples were assayed with SYBR Green Ready Master Mix (Takara Bio, Shiga, Japan) and appropriate primers (Supplementary Table S3) and analyzed using the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The relative RNA expression levels were calculated using the comparative threshold cycle (Ct) method, and glyceraldehyde 3-phosphate dehydrogenase was used as a control.
a

Post-lingual onset hearing loss patient in YUHL (n=192)

Audiogram pattern

Ski-slope

Flat, reverse or others

Patient consent for genetic testing fee covered by national insurance

Panel (n=32)

WES (n=69)

Panel (n=38)

WES (n=53)

Interpretation of genetic variants in deafness genes.

Monthly professional review conference on genotype-phenotype correlation in all patients.

Comparison of clinical characteristics (age of onset, severity, progression)

Pathogenic mutation (n=13)

Pathogenic mutation (n=18)

Pathogenic mutation (n=15)

Pathogenic mutation (n=22)

n=101

n=91

Diagnostic yield: 30.7%

Diagnostic yield: 40.7%

Novel Gene Discovery Process

b

Ski-slope group

Other group

Threshold (DB HL)

Frequency (Hz)

Patients with molecular diagnosis

Patients without molecular diagnosis
Fig. 1 Schematic workflow of genetic analysis in a prospective cohort of patients with post-lingual hearing loss and novel gene discovery in ski-slope hearing loss. a 192 families with post-lingual hearing loss were grouped into two groups, i.e., those with ski-slope audiogram patterns and others, and were subjected to genetic analysis via panel/exome sequencing. Genetic heterogeneity was observed in both the ski-slope hearing loss and other hearing loss groups. b Audiogram patterns presented by average frequency-specific dB thresholds were similar regardless of genetic diagnosis states in both groups.

**Immunofluorescence of mature murine cochlea samples**

Isolated cochlea samples from adult mice (C57BL/6 strain, 7 weeks) were obtained via microdissection. Tissues were fixed by submersion in 4% formaldehyde at 4°C overnight. After washing twice with phosphate-buffered saline (PBS), the fixed temporal bones were decalcified for 24 h in 10% EDTA/PBS. For paraffin sectioning, serial dehydation of the tissues was performed with ethanol and xylene. The paraffin blocks were sliced into 5-μm-thick sections in the mid-modiolar plane using a microtome (Leica Biosystems). Deparaffinization was performed on the sections, as well as the whole-mounted tissues, with a series of washes with xylene, ethanol, and PBS. The tissues were blocked with 10% donkey serum and incubated with target-specific primary and secondary antibodies (Supplementary Table S4) at 4°C overnight. The samples were then mounted with mounting solution (Sigma-Aldrich, St. Louis, MO, USA) and imaged using an LSM780 confocal microscope (Zeiss).

**Results**

**Differential diagnostic rates of post-lingual HL by known genes according to audiogram patterns**

Among 192 families with post-lingual HL included in this prospective study, the initial audiogram pattern analysis identified 101 patients (52.6%) with ski-slope HL (Fig. 1a). One-third of the YUHL cohort (n = 70/192) agreed to undergo genetic testing, resulting in gene panel test evaluation. Among 101 families in the ski-slope group, the final diagnostic yield was 30.7% (n = 31), including 37 variants in 17 genes. In particular, seven patients had pathogenic variants in three HL genes previously associated with ski-sloping HL (Song et al. 2020), namely, TMPRSS3, MYH14, and MYH9 (Supplementary Table S5). By contrast, the final genetic diagnostic yield was 40.7% in the other HL group, which was higher than that in the ski-slope group with consistent statistical significance in the chronological timeline (Figs. 1a, 2a). The relatively high proportions of TMPRSS3, MYH14, and MYH9 variants despite lower diagnostic rates in the ski-slope HL group confirmed the suitability of families selected from the YUHL cohort and enabled us to focus on rare genetic variants in the yet-to-be-investigated families.

**Association of HL phenotypes according to genetic diagnosis status**

The audiogram patterns in both the ski-slope group and other HL group did not present differences in terms of overall patterns and frequency-specific thresholds according to the genetically diagnosed status (Fig. 1b). When patients with post-lingual HL were classified into three subgroups according to age of onset, the probability for genetic diagnosis by known HL genes was significantly lower for the ski-slope group than for the other HL group in patients with HL onset under 40 years (Fig. 2b, Supplementary Fig. S1a, b). Furthermore, the ski-slope HL group showed a longer lag time until genetic testing in diagnosed and undiagnosed patients compared with the other HL group (p = 0.021; Fig. 2c, Supplementary Fig. S1c), suggesting delays in both genetic testing and diagnosis in the ski-slope group. Although the ski-slope HL group showed a significantly lower prevalence of vestibular symptoms (p < 0.001), the presence of vestibular symptoms did not lead to higher diagnostic rates in either the ski-slope group or the other HL group (p = 0.098; Fig. 2d).

By contrast, the diagnostic rates of simplex families were substantially lower in the ski-slope HL group than in the other HL group (Fig. 2e).

**Selection of the candidate gene, DLL1**

Based on the overall diagnostic rate of 35.4% (68/192) in post-lingual HL by currently validated deafness-associated genes, further analysis of ES from the 51 genetically undiagnosed patients in the ski-slope HL group enabled the identification of 4696 rare variants with allele frequencies less than 0.001 or 0.006, based on their inheritance patterns (Rim et al. 2019); these were further filtered out by comparing their values with those of healthy control samples (Fig. 3a). After manually curating genes with rare variants in multiple individuals, 26 candidate genes were prioritized, based on our evidence, which included details, such as gene features, variant analyses, and clinical characteristics (Supplementary Table S6). DLL1 (MIM 606582), which encodes delta-like 1, was the top scoring candidate gene, based on evidence obtained after analyzing the following aspects: (1) gene-by-gene analysis: no LoF variant was observed in gnomAD, a deaf mouse model in IMPC, and publications.
Notch signaling via coculture assays (Supplementary Fig. S2a). Interestingly, the surface biotinylation experiment revealed that the membrane expression levels of DLL1 were expressed in the membrane in the same manner as that of wild-type (WT) DLL1 (Supplementary Fig. S2b, c). By contrast, all three variants (i.e., p.C179F, p.V644M, and p.P470L) were observed at evolutionary conserved regions (Supplementary Table S7); and (3) all variants were segregated in affected members of three unrelated families with autosomal dominant inheritance and ski-slope audiogram (Fig. 3b, c).

Variants in DLL1 conferred Notch signaling gain-of-function in vitro

To investigate the effects of missense variants detected in the ski-slope HL group, we first examined membrane expression levels of four DLL1 variants (Fig. 3d), including another DLL1 missense variant (c.536G>T [p.C179F, M4]), which was recently reported to be responsible for a congenital neurodevelopmental disorder (MIM 618709) with an autosomal dominant inheritance (Fischer-Zirnsak et al. 2019). Pathogenic DLL1 variants linked to the neurodevelopmental disorder were predicted to exhibit the LoF effect; indeed, the DLL1 p.C179F (M4) variant was trapped intracellularly, which revealed the presence of a trafficking defect (Supplementary Fig. S2a). By contrast, all three DLL1 variants (i.e., p.G399S [M1], p.V644M [M2], and p.P470L [M3]) identified in this study were expressed in the membrane in the same manner as that of wild-type (WT) DLL1 (Supplementary Fig. S2a). Interestingly, the surface biotinylation experiment revealed that the membrane expression levels of DLL1 variants p.V644M and p.P470L were increased, and the incremental values were statistically significant compared with those for WT DLL1 (Supplementary Fig. S2b, c). Although the membrane expression levels of p.G399S did not show a significant increase, CUPSAT (Parthiban et al. 2006), one of the most widely used protein stability prediction tools, proposed the increased stability for p.G399S (ΔΔG = 0.98) and reduced stability for p.C179F (ΔΔG = −7.49).

Next, we investigated the effects of DLL1 variants on Notch signaling via coculture assays (Supplementary Fig. S3a). Experimental feasibility for Notch activation levels in coculture assays and for appropriate antibodies enabled us to exclude the effects of endogenous NOTCH1 and/or DLL1 expression (Supplementary Fig. S3b–d). When co-cultured with NOTCH1-expressing cells, the expression levels of the Notch intracellular domain (NICD), as well as HES1 (MIM 139605) and HES5 (MIM 607348), two target genes of NICD (Zine et al. 2001), were increased in all three variants (M1, M2, and M3), compared with those with WT DLL1, suggesting that these variants caused gain-of-function Notch activation (Fig. 4a, b). Interestingly, the M4 variant, which was predicted to result in an LoF effect in a previous publication (Fischer-Zirnsak et al. 2019), caused the downregulation of Notch signaling, compared with expression with WT DLL1 (Fig. 4a, b). Furthermore, the activation or downregulation of Notch signaling via changes in mRNA were within the twofold range in real-time PCR experiments (Supplementary Fig. S3e).

Expression patterns of DLL1 and NOTCH1 in mature murine cochlea

Although the roles of ligands causing Notch signaling activation, including DLL1 and Jagged 1/2, have been elucidated in cochlear development processes for the accurate patterning of auditory hair cell differentiation, it is unclear whether Notch signaling is involved in homeostasis in the adult cochlea (Takebayashi et al. 2007; Zine et al. 2000). To explore this aspect, DLL1 and NOTCH1 expression patterns were examined via immunofluorescence analysis in mature murine cochlea (Supplementary Fig. S4a–c). In cochlea from 7-week-old mice, DLL1 was expressed in supporting cells, including inner phalangeal cells, pillar cells, and Deiters’ cells (Supplementary Fig. S4a, c), whereas NOTCH1 was strongly expressed in the inner hair cells and weakly expressed in the outer hair cells (Supplementary Fig. S4b, c). By contrast, DLL1 and NOTCH1 were mainly expressed in the hair and supporting cells, respectively, in the embryonic and postnatal cochlea (Supplementary Fig. S4d–f), consistent with the results of previous reports (Basch et al. 2016; Zine et al. 2000). To investigate DLL1 and NOTCH1 expression in a tonotopy gradient, fluorescence intensities normalized to those of 4′,6-diamidino-2-phenylindole (DAPI) were measured in whole mount samples. While DLL1 expression levels were similar across all areas (Fig. 4c), NOTCH1 expression levels were lowest at the apex and highest at the base, indicating a gradient pattern with statistical significance (Fig. 4c). From these data, we observed that NOTCH1 expression was gradually decreased in hair cells from the basal turn, tuned at high frequencies, to the apical turn; this might be relevant to HL vulnerabilities at high frequencies.
a) Exome sequencing of 51 ski-slope hearing loss patients without molecular diagnosis

- Rare variant selection; Allele frequency < 0.1% (in autosomal dominant) or 0.6% (in autosomal recessive)
- Filter out variants with internal control sample
- Variants found in multiple patients
- Manual curation
- 4896 variants in 1888 genes
- 3346 variants in 1765 genes
- 435 variants in 185 genes
- 26 genes

- ADAMTS11, AKNK, ARHGAP1, ARHGEF10L, ASNT1, CILP, COL6A2, DLL1, DNAH1, DYNC2H1, EP400, HYDIN, NGSF3, LONP1, LRP2, MYCBP2, MYOF, NFKB2, NKC, PLEKHG4, RBP19, RPUSD1, SRRM2, THAP9, TMTSF3, TTC29

b) YUHL106

- Mutation 1 (M1)
  - DLL1 c.1195G>A p.G399S

- YUHL196

- Mutation 2 (M2)
  - DLL1 c.1939G>A p.V644M

- YUHL80

- Mutation 3 (M3)
  - DLL1 c.1409C>T p.P470L

c) YUHL106 II-1

- Frequency (Hz)
  - 250 500 1K 2K 4K 8K

- Hearing threshold (dB)

- YUHL196 II-1

- Frequency (Hz)
  - 250 500 1K 2K 4K 8K

- Hearing threshold (dB)

- YUHL196 II-2

- Frequency (Hz)
  - 250 500 1K 2K 4K 8K

- Hearing threshold (dB)

- YUHL80 II-1

- Frequency (Hz)
  - 250 500 1K 2K 4K 8K

- Hearing threshold (dB)

d) Extracellular region

- C179F (M1)
- G399S (M1)
- P470L (M3)
- V644M (M2)

- DSL domain
- MAGI1 interacting domain
- PDZ ligand domain

- Intracellular region

- 8 EGF-like repeats
- Transmembrane domain
Clinical ES, which may not be able to identify other patho-
identification of novel candidate genes and subsequent func-
landscape require a more extensive genetic workup for the
diseases or even disease subtypes with lower rates
focusing on the specific phenotype of the ski-slope audio-
reached similar yields compared with those with pre-lingual
from simplex families. These results indicated that
more efforts are needed for accurate and timely genetic diag-
the longer deafness duration and lag time until genetic testing, potentially related to the
milder disease severity.
The additional genetic components responsible for
hereditary HL are still unclear, as more than 500 genes are
expected to be related to deafness onset (Bowl et al. 2017;
Ingham et al. 2019). Although the diagnostic rates based on
known pathogenic variants in patients with post-lingual HL
reached similar yields compared with those with pre-lingual
and severe HL (Sheppard et al. 2018), genetic delineation
focusing on the specific phenotype of the ski-slope audiogram pattern resulted in a lower diagnostic rate and, there-
fore, a higher chance for novel candidate gene discovery. In
particular, diseases or even disease subtypes with lower rates of
genetic diagnosis based on the currently known genetic
landscape require a more extensive genetic workup for the
identification of novel candidate genes and subsequent func-
tional validations, despite limitations in currently available
clinical ES, which may not be able to identify other patho-
genic noncoding or epigenetic variants.

Based on our functional study results, individuals born
with germline missense gain-of-function variants in DLL1
may not exhibit defects as severe as those with other genetic
diseases, owing to LoF variants in genes involved in Notch
signaling. However, Notch signaling overactivation was
induced in individuals with rare DLL1 missense variants
compared with that in individuals without DLL1 variants
under physiological conditions, possibly resulting from
acoustic trauma and senescence. As the cumulative effects
of Notch signaling overactivation increased during the adulthood, these patients remained susceptible to post-lingual
ski-slope HL because of the deleterious effects of DLL1
variants. The gradient expression pattern of NOTCH1 recep-
tors revealed in this study may contribute to high frequency-
specific hearing impairments. Furthermore, the post-lingual
phenotype may also be associated with the incomplete pen-
etrance of DLL1 missense variants. Indeed, the relatively
high allele frequency in the gnomAD database (particularly
for p.P470L; 0.03%) suggested that the effects of certain
variants present interindividual variability or that gene–envi-
ronment or gene–host interactions may affect variant carriers
in different ways.

Recently, variations in Notch signaling in mature adult
organs have been shown to be closely related to various
human diseases, such as liver cirrhosis (Zhu et al. 2018),
glucose intolerance (Bartolome et al. 2019), and schizophre-
nia (Ables et al. 2011). Numerous studies have investigated
the roles of Notch signaling during cochlear development
and regeneration, evaluating their expression patterns, spa-
tiotemporal dynamics, and regulation (Nandagopal et al.
2018). Interestingly, a recent study on the adult mouse coch-
lea proved that only the transiently overexpressed NICD and
Myc are essential for survival and the ability of supporting
cells to undergo transdifferentiation for regeneration (Shu
et al. 2019). However, continuously sustained signals of
either NICD or Myc are detrimental to hair cell differentia-
tion, because the targets of NICD, i.e., Hes1 and Hes5, are
antagonists of Atoh1, which is a key player in hair cell dif-
ferentiation (Shu et al. 2019; Zheng et al. 2000). Neverthe-
less, few studies have focused on the associations between
germline variants in Notch signaling component genes and
altered functions of the mature adult cochlea (Terrinoni et al.
2013). Our results highlight opportunities for the genetic
diagnosis of ski-slope HL and the discovery of novel thera-
peutic agents, consistent with the results of current clinical
trials examining Notch signaling inhibitors for adult-onset
HL (Andersson and Lendahl 2014) and a proof-of-concept
study regarding hair cell regeneration in adult guinea pigs
through siRNA Hes1 modulation (Du et al. 2018), based
on the evidence that Notch signaling inhibition promotes

**Discussion**

Various genetic studies on HL using panel sequencing and/
or ES previously evaluated clinical efficiency according to
etnicity, age of onset, or severity (Kim et al. 2020; Shearer
et al. 2014; Yuan et al. 2020). However, few studies have
investigated the diagnostic rates of genetic testing in relation
to audiogram patterns (Song et al. 2020), which is the
first-line diagnostic tool in HL evaluation. In our prospective
study, the genetic diagnostic rates of patients with post-lingual
HL were consistently lower in the ski-slope HL group
than in the other HL group. Interestingly, approximately 20%
of genetically diagnosed patients carried pathogenic muta-
tions in recessive genes, even though our cohort consisted
of patients with post-lingual HL, suggesting a complex relation-
ship between inheritance mode and age of onset. More-
over, the ski-slope HL group showed a lower probability
for genetic diagnosis, particularly in patients with early HL
onset from simplex families. These results indicated that
more efforts are needed for accurate and timely genetic diag-
nosis of ski-slope HL, despite the longer deafness duration
and lag time until genetic testing, potentially related to the
milder disease severity.
differentiation into hair cells in the cochlea (Atkinson et al. 2015; Mizutari et al. 2013).

In conclusion, comprehensive genetic diagnosis using panel sequencing/ES in a prospective cohort of patients with post-lingual HL revealed differential diagnostic rates according to audiogram patterns. In further analyses of the genetically undiagnosed ski-slope audiogram group, DLL1 missense variants were identified as genetic components resulting from the overactivation of Notch signaling, the degree of which appear to be within the acceptable range during development. Functional studies demonstrated that DLL1 missense variants resulted in gain-of-function effects, whereas a DLL1 variant reportedly associated with a neurodevelopmental disorder was proven to be associated with the LoF effect. Notch signaling in the mature adult cochlea is thus altered by genetic variants contributing to the

Fig. 4 Functional in vitro and in vivo experiments suggesting gain-of-function effects of DLL1 variants and deleterious effects of Notch signaling overactivation on the mature cochlea. a, b Immunoblotting results of downstream markers of Notch signaling activation (NICD, HES1, and HES5) were obtained using a coculture assay to analyze Notch signaling activation by wild-type and variant DLL1 (Supplementary Fig. S3a). c The expression levels of DLL1 (left panel) and NOTCH1 (right panel) according to tonotopy, from the apex to base in whole-mount samples of cochlear tissues from 7-week-old mice and their quantification; the fluorescence levels were normalized with the DAPI fluorescence intensity values. The data represent the means ± standard errors of the means. *p < 0.05, **p < 0.01, ***p < 0.001. Scale bars: 20 μm (c). DIC differential interference contrast microscopy images.
development of ski-slope HL, in combination with aging and acoustic traumas.

**Supplementary Information** The online version contains supplementary material available at [https://doi.org/10.1007/s00439-021-02367-z](https://doi.org/10.1007/s00439-021-02367-z).

**Acknowledgements** We thank all individuals who participated in this study. This study was supported by the Team Science Award (6-2021-0002 and -0003) of Yonsei University College of Medicine and by the Basic Science Research Program of the National Research Foundation of Korea (NRF) (MSIT; 2018R1A1A2A0205079 and 2021R1A2C2035549 to HYG, and 2019R1A2C1084033 to JJ) and the Ministry of Health and Welfare, Republic of Korea (H18C0160 to JYC). We also thank Medical Illustration and Design, part of the Medical Research Support Services of Yonsei University College of Medicine, for all artistic support related to this work.

**Author contributions** JJ, JYC, and HYG contributed to the conception and design of this study; DHK, CJY, and JJ referred the patients to this study; JHR, SYJ, JAK, HYK, JEY, and HYG analyzed WES data; JHR, STL, JJ, and JYC analyzed gene panel data; JHR, BN, and KK performed mouse experiments and histology; JHR, YIK, and KSO performed cell experiments; JWB, MGL, JJ, CJY, and HYG performed data analysis and contributed to data interpretation; JJ, CJY, and HYG wrote the manuscript. All the authors revised the manuscript and approved the final version for publication.

**Data availability** The data sets generated during and/or analyzed during the current study will be available from the corresponding author on request.

**Declarations**

**Conflict of interest** The authors state that there are no conflicts of interest to declare.

**Ethical statement** This study was approved by the institutional review board of Severance Hospital, Yonsei University Health System (IRB #4-2015-0659).

**Informed consent** Yonsei University Health System (IRB #4-2015-0659). We obtained informed written consent from individuals with HL for their participation in this study and the publication of their clinical data.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

**References**

Ables JL, Breunig JJ, Eisch AJ, Rakic P (2011) Not(ch) just development: Notch signaling in the adult brain. Nat Rev Neurosci 12:269–283. [https://doi.org/10.1038/nrn3024](https://doi.org/10.1038/nrn3024)

Andersson ER, Lendahl U (2014) Therapeutic modulation of Notch signalling—are we there yet? Nat Rev Drug Discov 13:357–378. [https://doi.org/10.1038/nrd4252](https://doi.org/10.1038/nrd4252)

Atkinson PJ, Huarayca Najarro E, SayyidZN, Cheng AG (2015) Sensory hair cell development and regeneration: similarities and differences. Development 142:1561–1571. [https://doi.org/10.1242/dev.114926](https://doi.org/10.1242/dev.114926)

Aziaie H, Booth KT, Ephraim SS, Crone B, Black-Ziegelbein EA, Marini RJ, Shearer AE, Sloan-Heggen CM, Kolbe D, Casavant T, Schnieders MJ, Nishimura C, Braun T, Smith RJH (2018) Genomic landscape and mutational signatures of deafness-associated genes. Am J Hum Genet 103:484–497. [https://doi.org/10.1016/j.ajhg.2018.08.006](https://doi.org/10.1016/j.ajhg.2018.08.006)

Bartolome A, Zhu C, Susser L, Pajvani UB (2019) Notch signaling dynamically regulates adult β cell proliferation and maturity. J Clin Invest 129:268–280. [https://doi.org/10.1172/jci98098](https://doi.org/10.1172/jci98098)

Basch ML, Brown RM 2nd, Jen HI, Semerci F, Depreux E, Edlund RK, Zhang H, Norton CR, Gridley T, Cole SE, Doetzlhofer A, Maletic-Savatic M, Segil N, Groves AK (2016) Fine-tuning of Notch signaling sets the boundary of the organ of Corti and establishes sensory cell fates. Elife. [https://doi.org/10.7554/eLife.19921](https://doi.org/10.7554/eLife.19921)

Bowl MR, Simon MM, Ingham NJ, Greenaway S, Santos L, Cather H, Taylor S, Mason J, Kurbatova N, Pearson S, Bower LR, Clary DA, Meziane H, Reilly P, Minowa O, Kelsey L, Tocchi-Valentini GP, Gao X, Bradley A, Skarnes WC, Moore M, Beaudet AL, Justice MJ, Seavitt J, Dickinson ME, Wurst W, de Angelis MH, Herault Y, Wakana S, Nutter LJM, Flenniken AM, McKerlie C, Murray SA, Svenson KL, Braun RE, West DB, Lloyd KCK, Adams DJ, White J, Karp N, Flicek P, Smedley D, Meehan TF, Parkinson HE, Teboul LM, Wells S, Steel KP, Mallon A-M, Brown SDM (2017) A large scale hearing loss screen reveals an extensive unexplored genetic landscape for auditory dysfunction. Nat Commun 8:886. [https://doi.org/10.1038/s41467-017-00595-4](https://doi.org/10.1038/s41467-017-00595-4)

Chung J, Park SM, Chang SO, Chung T, Lee KY, Kim AR, Park JH, Kim V, Park WY, Oh SH, Kim D, Park WJ, Choi BY (2014) A novel mutation of TMPSRSS3 related to milder auditory phenotype in Korean postlingual deafness: a possible future implication for a personalized auditory rehabilitation. J Mol Med (berl) 92:651–663. [https://doi.org/10.1007/s00109-014-1128-3](https://doi.org/10.1007/s00109-014-1128-3)

Cunningham LL, Tucci DL (2017) Hearing loss in adults. N Engl J Med 377:2465–2473. [https://doi.org/10.1056/NEJMoa1616601](https://doi.org/10.1056/NEJMoa1616601)

Dai P, Huang LH, Wang GJ, Gao X, Qu CY, Chen XW, Ma FR, Zhang J, Xing WL, Xi SY, Ma BR, Pan Y, Cheng XH, Duan H, Yuan YY, Zhao LP, Chang L, Gao RZ, Liu HH, Zhang W, Huang SS, Kang DY, Liang W, Zhang K, Jiang H, Guo YL, Zhou Y, Zhang WX, Lyu F, Jin YN, Zhou Z, Lu HL, Zhang X, Liu P, Ke J, Hao JS, Huang HM, Jiang D, Ni X, Long M, Zhang L, Qiao J, Morton CC, Liu XL, Zheng C, Han DM (2019) Concurrent hearing and genetic screening of 180,469 neonates with follow-up in Beijing, China. Am J Hum Genet 105:803–812. [https://doi.org/10.1016/j.ajhg.2019.09.003](https://doi.org/10.1016/j.ajhg.2019.09.003)

Dickinson ME, Flenniken AM, Ji X, Teboul L, Wong MD, White J, McEwan TF, Weninger WJ, Westerberg H, Adisus H, Baker CN, Bower L, Brown JM, Caddle LB, Chiani F, Clary D, Cleak JK, Daly MJ, Denegre JM, Doe B, Dolan ME, Edie SM, Fuchs H, Gaillat-Durner V, Galli A, Gambadoro A, Gallegos J, Guo S, Horner NR, Hsu CW, Johnson SJ, Kalaga S, Keith LC, Lanoue L, Lawson TN, Lek M, Mark M, Marschall S, Mason J, McElwee ML, Newbigging S, Nutter LM, Peterson KA, Ramirez-Solis R, Rowland DJ, Ryder E, Samocha KE, Seavitt JR, Atkinson PJ, Huarayca Najarro E, SayyidZN, Cheng AG (2015) Sensory hair cell development and regeneration: similarities and differences. Development 142:1561–1571. [https://doi.org/10.1242/dev.114926](https://doi.org/10.1242/dev.114926)
Selloum M, Szoke-Kovacs Z, Tamura M, Trainor AG, Tudose I, Wakana S, Warren J, Wendling O, West DB, Wong L, Yoshih A, MacArthur DG, Tocchini-Valentini GP, Gao X, Flicek P, Bradley A, Skarnes WC, Justice MJ, Parkinson HE, Moore M, Wells S, Braun RE, Svensson KL, de Angelis MH, Herault Y, Mohun T, Mallon AM, Henkelman RM, Brown SD, Adams DJ, Lloyd KC, McKerlie C, Beaudet AL, Bucan M, Murray SA (2016) High-throughput discovery of novel developmental phenotypes. Nature 537:508–514. https://doi.org/10.1038/nature19356

DiStefano MT, Hemphill SE, Oza AM, Siegert RK, Grant AR, Hughes MY, Cushman BJ, Azaiez H, Booth KT, Chapin A, Duzkale H, Matsunaga T, Shen J, Zhang W, Kenna M, Schimenti LA, Tekin M, Rehm HL, Tayoun ANA, Amr SS (2019) ClinGen expert clinical validity curration of 164 hearing loss gene-disease pairs. Genet Med 21:2239–2247. https://doi.org/10.1038/s41436-019-0487-0

Du X, Cai Q, West MB, Youn I, Huang X, Li W, Cheng W, Nakmali D, Ewert DL, Kopke RD (2018) Regeneration of cochlear hair cells and hearing recovery through Hes1 modulation with siRNA nanoparticles in adult Guinea pigs. Mol Ther 26:1313–1326. https://doi.org/10.1016/j.ymthe.2018.03.004

Fischer-Zirnsak B, Segebrecht L, Schubach M, Charles P, Alderman E, DiStefano MT, Hemphill SE, Oza AM, Siegert RK, Grant AR, Hughes MY, Cushman BJ, Azaiez H, Booth KT, Chapin A, Duzkale H, Matsunaga T, Shen J, Zhang W, Kenna M, Schimenti LA, Tekin M, Rehm HL, Tayoun ANA, Amr SS (2019) ClinGen expert clinical validity curration of 164 hearing loss gene-disease pairs. Genet Med 21:2239–2247. https://doi.org/10.1038/s41436-019-0487-0

Kim BJ, Oh DY, Han JH, Oh J, Kim MY, Park HR, Seok J, Cho SD, Lee SY, Kim Y, Carandang M, Kwon IS, Lee S, Jang JH, Chung YH, Lee S, Lee H, Hwang SM, Choi BY (2020) Significant Mendelian genetic contribution to pediatric mild- to-moderate hearing loss and its comprehensive diagnostic approach. Genet Med 22:1119–1128. https://doi.org/10.1038/s41436-020-0774-9

Mizutari K, Fujioka M, Hosmos M, Bramhall N, Okano H, Okano H, Edge AS (2013) Notch inhibition induces cochlear hair cell regeneration and recovery of hearing after acoustic trauma. Neuron 77:58–69. https://doi.org/10.1016/j.neuron.2012.10.032

Nandagopal N, Santat LA, LeBon L, Sprinzak D, Bronner ME, Elowitz MB (2018) Dynamic ligand discrimination in the Notch signaling pathway. Cell 172:869–880.e1819. https://doi.org/10.1016/j.cell.2018.01.002

Oza AM, DiStefano MT, Hemphill SE, Cushman BJ, Grant AR, Siegert RK, Shen J, Chapin A, Boczek NJ, Schimenti LA, Murby JR, Hasadasi L, Nara K, Kenna M, Booth KT, Azaiez H, Griffith A, Avraham KB, Kremer H, Rehm HL, Amr SS, Abou Tayoun AN (2018) Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss. Hum Mutat 39:1593–1613. https://doi.org/10.1002/humu.23630

Parthiban V, Gromiha MM, Schomburg D (2006) CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res 34:W239-242. https://doi.org/10.1093/nar/gkl190

Rim JH, Lee JS, Jung J, Lee JH, Lee ST, Choi JR, Choi JY, Lee MG, Gee HY (2019) Systematic evaluation of gene variants linked to hearing loss based on allele frequency threshold and filtering allele frequency. Sci Rep 9:43583. https://doi.org/10.1038/s41598-019-41068-6

Soheir AE, Eppsteiner RW, Booth KT, Ephraim SS, Gurrola J 2nd, Simpson A, Black-Ziegelbein EA, Joshi S, Ravi H, Giuffre A, Happe S, Hildebrand MS, Azaiez H, Bayazit YA, Erdal ME, Lopez-Escamez JA, Gazquez I, Tamayo ML, Gelvez NY, Leal GL, Jals J, Ekstein J, Yang T, Usami S, Kahrizi K, Bazaz-Zadegan N, Najmabadi H, Schetzee TE, Braun TA, Casavant TL, LeProust EM, Smith RJ (2014) Utilizing ethnicity-specific differences in minor allele frequency to recategorize reported pathogenic deafness variants. Am J Hum Genet 95:445–453. https://doi.org/10.1016/j.ajhg.2014.09.001

Shearer AE, Shen J, Amr S, Morton CC, Smith RJ (2019) A proposal for comprehensive newborn hearing screening to improve identification of deaf and hard-of-hearing children. Genet Med 21:2615–2630. https://doi.org/10.1038/s41436-019-0563-5

Sheppard S, Biswas S, Li MH, Jayaraman V, Slack I, Romasko EJ, Sisson A, Brunton J, Rajagopalan R, Sarmady M, Abrudan JL, Jairam S, DeChene ET, Ying X, Choi J, Wilkens A, Raible SE, Scarnano MI, Santani A, Pennington JW, Loo M, Conlin LK, Devkota B, Dulik MC, Spinner NB, Kranitz ID (2018) Utility and limitations of exome sequencing as a genetic diagnostic tool for children with hearing loss. Genet Med 20:1663–1676. https://doi.org/10.1038/s41436-018-0004-x
Shu Y, Li W, Huang M, Quan YZ, Scheffer D, Tian C, Tao Y, Liu X, Hochledinger K, Indzhykulian AA, Wang Z, Li H, Chen ZY (2019) Renewed proliferation in adult mouse cochlea and regeneration of hair cells. Nat Commun 10:5530. https://doi.org/10.1038/s41467-019-13157-7

Song MH, Jung J, Rim JH, Choi HJ, Lee HJ, Noh B, Lee JS, Gee HY, Choi JY (2020) Genetic inheritance of late-onset, downsloping hearing loss and its implications for auditory rehabilitation. Ear Hear 41:114–124. https://doi.org/10.1097/aud.0000000000000734

Takebayashi S, Yamamoto N, Yabe D, Fukuda H, Kojima K, Ito J, Honjo T (2007) Multiple roles of Notch signaling in cochlear development. Dev Biol 307:165–178. https://doi.org/10.1016/j.ydbio.2007.04.035

Taylor KR, Deluca AP, Shearer AE, Hildebrand MS, Black-Ziegelbein EA, Anand VN, Sloan CM, Eppsteiner RW, Scheetz TE, Huygen PL, Smith RJ, Braun TA, Casavant TL (2013) AudioGene: predicting hearing loss genotypes from phenotypes to guide genetic screening. Hum Mutat 34:539–545. https://doi.org/10.1002/humu.22268

Terrinoni A, Serra V, Bruno E, Strasser A, Valente E, Flores ER, van Bokhoven H, Lu X, Knight RA, Melino G (2013) Role of p63 and the Notch pathway in cochlea development and sensorineural deafness. Proc Natl Acad Sci U S A 110:7300–7305. https://doi.org/10.1073/pnas.1214498110

Wang Q, Xiang J, Sun J, Yang Y, Guo L, Wang H, Chen Y, Leng J, Wang X, Zhang J, Han B, Zou J, Yan C, Zhao L, Luo H, Han Y, Yuan W, Zhang H, Wang W, Wang J, Yang H, Xu X, Yin Y, Morton CC, Zhao L, Zhu S, Shen J, Peng Z (2019) Nationwide population genetic screening improves outcomes of newborn screening for hearing loss in China. Genet Med 21:2231–2238. https://doi.org/10.1038/s41436-019-0481-6

Wilson BS, Tucci DL, Merson MH, O’Donoghue GM (2017) Global hearing health care: new findings and perspectives. Lancet 390:2503–2515. https://doi.org/10.1016/s0140-6736(17)31073-5

Yuan Y, Li Q, Su Y, Lin Q, Gao X, Liu H, Huang S, Kang D, Todd NW, Mattox D, Zhang J, Lin X, Dai P (2020) Comprehensive genetic testing of Chinese SNHL patients and variants interpretation using ACMG guidelines and ethnically matched normal controls. Eur J Hum Genet 28:231–243. https://doi.org/10.1038/s41431-019-0510-6

Zheng JL, Shou J, Guillemot F, Kageyama R, Gao WQ (2000) Hes1 is a negative regulator of inner ear hair cell differentiation. Development 127:3373–3383

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.